| Patent application number | Description | Published |
|---|
| 20080207904 | Imatinib base, and imatinib mesylate and processes for preparation thereof - The present invention provides crystalline forms of imatinib base, imatinib base free of desmethyl imatinib, and imatinib mesylate free of desmethyl imatinib mesylate, processes of their preparation and pharmaceutical compositions of imatinib mesylate. | 08-28-2008 |
| 20080234516 | Processes for preparing solid states of O-desmethylvenlafaxine succinate - Provided are processes for the preparation of amorphous O-desmethylvenlafaxine and for the preparation of crystalline forms I, II, III, and IV of O-desmethylvenlafaxine. | 09-25-2008 |
| 20080254520 | Method for reducing impurity level in mycophenolic acid fermentation - The present invention relates to methods for reducing impurities of mycophenolic acid during fermentation by controlling the level of carbon source during fermentation of mycophenolic acid and for the isolation and use as a standard marker of the impurity homo-mycophenolic acid. | 10-16-2008 |
| 20080262223 | Isolation of Galanthamine From Biological Material - The subject matter of present invention relates to the process for isolation and purification of galanthamine and its derivatives produced by numerous plants. | 10-23-2008 |
| 20080287378 | Solid state forms of 5-azacytidine and processes for preparation thereof - The present invention provides novel crystalline forms of 5-deazacytidine, and pharmaceutical compositions comprising these novel forms. The invention also provides methods for the preparation of the novel forms and compositions. | 11-20-2008 |
| 20080312447 | Process for Isolation of Crystalline Tacrolimus - The invention is a simple process for separation of tacrolimus and its analogues, ascomycin and tsucubamycin B and preparation of enough pure crystalline tacrolimus. The process takes advantage of surprising properties of tacrolimus and involves extraction, purification and crystallization to produce purified crystalline tacrolimus. | 12-18-2008 |
| 20090012182 | Crystal forms of O-desmethylvenlafaxine succinate - Provided are crystalline forms of O-desmethylvenlafaxine succinate, methods for their preparation, and pharmaceutical composition thereof. | 01-08-2009 |
| 20090012295 | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib - The present invention provides amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib. | 01-08-2009 |
| 20090012296 | Processes for the preparation of crystalline form beta of imatinib mesylate - Provided is a process for the preparation of crystalline form β of Imatinib mesylate. | 01-08-2009 |
| 20090042839 | Crystalline forms of ibandronate sodium - Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof. | 02-12-2009 |
| 20090105346 | Novel crystalline forms of armodafinil and preparation thereof - The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the invention. | 04-23-2009 |
| 20090118297 | POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF - Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. | 05-07-2009 |
| 20090124642 | Crystalline forms of Erlotinib HCI and formulations thereof - The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof. | 05-14-2009 |
| 20090192200 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF - Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof. | 07-30-2009 |
| 20090264438 | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha - Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described. | 10-22-2009 |
| 20100004449 | CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL - The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). | 01-07-2010 |
| 20100130458 | Polymorphs of fluticasone furoate and process for preparation thereof - Provided are polymorphs of fluticasone furoate and processes for preparation thereof. | 05-27-2010 |
| 20100240629 | POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furoate and at least one pharmaceutically acceptable excipient; and the use of the crystalline forms of Fluticasone furoate in the preparation of pharmaceutical formulations. | 09-23-2010 |
| 20110097398 | REDUCTION OF CROSS-LINKING GELATIN IN GELATIN CAPSULES - The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication agent, or in combinations thereof. Described are soft gelatin capsules characterized by improved stability as compared with gelatin capsules that do not contain amino acid in the shell and carboxylic acid ester in the filling, shell or in the lubrication agent, or in combinations thereof. | 04-28-2011 |
| 20110118477 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS - Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate. | 05-19-2011 |
